Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 15.68 USD 0.38% Market Closed
Market Cap: 2.1B USD

During the last 3 months Aurinia Pharmaceuticals Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 27% over this period (open performance analysis).

The last transaction was made on Aug 5, 2025 by Tang Kevin , who bought 2.3m USD worth of AUPH shares.

Last Transactions:
Tang Kevin
$+2.3m
Tang Kevin
$+1.1m
Keenan Greg
$-210k
Tang Kevin
$+10.1m
Keenan Greg
$-68.4k
Tang Kevin
$+1.2m
Miller Joseph M
$-444.7k
Robertson Stephen P.
$-456.2k
Donley Matthew Maxwell
$-467.2k
Greenleaf Peter
$-1.3m
Keenan Greg
$-97.9k
Greenleaf Peter
$-1.6m
Tang Kevin
$+802.7k
Miller Joseph M
$-494.9k
Robertson Stephen P.
$-519k
Donley Matthew Maxwell
$-527.2k
Tang Kevin
$+3.1m
Tang Kevin
$+4.5m
Tang Kevin
$+3.6m
Tang Kevin
$+2.7m
Bailey Jeffrey Allen
$-38.4k
Smith Karen L.
$-44.2k
Habig Scott Michael
$-96.9k
Balakrishnan Brinda
$-3k
Billen Daniel
$-30.1k
Jayne David R.w.
$-28.4k
Leversage Jill
$-32.2k
Mackay-Dunn R. Hector
$-32.3k
Greenleaf Peter
$-711.1k
Miller Joseph M
$-194.9k
Donley Matthew Maxwell
$-224.1k
Habig Scott Michael
$-99.6k
View All Transactions

During the last 3 months Aurinia Pharmaceuticals Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 27% over this period (open performance analysis).

The last transaction was made on Aug 5, 2025 by Tang Kevin , who bought 2.3m USD worth of AUPH shares.

Sold
0-3
months
0 USD
0
3-6
months
210k USD
1
6-9
months
0 USD
0
9-12
months
5.9m USD
5
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
1
13.6m USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
1
5.1m USD

Aurinia Pharmaceuticals Inc
Insider Trading Chart

Aurinia Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Aurinia Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Aurinia Pharmaceuticals Inc
Glance View

Market Cap
2.1B USD
Industry
Biotechnology

In the heart of the pharmaceutical world, Aurinia Pharmaceuticals Inc. has carved out a niche with its focus on tackling autoimmune diseases, primarily targeting lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus. This Canadian company made waves with the development and approval of its flagship product, Lupkynis (voclosporin), an oral medication designed to treat this specific condition. By addressing a critical unmet need for patients grappling with the debilitating effects of lupus nephritis, Aurinia not only provides a precious lifeline for many but also positions itself as a significant player within the rare disease market. The development of Lupkynis was not just a scientific endeavor; it was a strategic move backed by rigorous clinical trials that underscored the efficacy and safety needed to gain regulatory approval and, ultimately, market trust. Aurinia’s revenue stream is primarily generated through the commercialization of Lupkynis, which has proved crucial in building its financial foundation. The company has embraced a commercialization strategy that involves direct sales, supported by partnerships and collaborations that enhance its reach and distribution capabilities. This approach allows Aurinia to maintain a strong connection to the markets it serves, providing valuable insights into emerging patient needs and market trends. Meanwhile, the company’s robust pipeline reflects its commitment to innovation, featuring additional immunology-focused therapies that could, over time, broaden its portfolio and potentially unlock new revenue streams. Integral to Aurinia’s success is its strategic focus on niche areas where the competition may be limited, giving it a distinctive edge in the complex world of pharmaceutical development.

AUPH Intrinsic Value
12.63 USD
Overvaluation 19%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top